UNI-PHARMA has recently secured a European Patent (EP4181693B1) for Hepatrat®, an innovative dietary supplement in dual-layer tablet form. Hepatrat® contains vitamin C, vitamin E, choline, as well as natural Ampelopsis grossedentata extract, standardized to consistent dihydromyricetin (DHM) content.
UNI-PHARMA’s Hepatrat: European patent & new publication on its contribution to fatty liver patients
This specific formulation has been designed to support normal liver function, contribute to the physiological function of liver cells and normal lipid metabolism, through a combination of ingredients with known antioxidant and anti-inflammatory properties.
The effectiveness and safety of Hepatrat® were evaluated in a randomized, double-blind, placebo-controlled 12-month clinical study conducted in Greece at outpatient hepatology clinics of three Athens hospitals (Laiko, Attiko and Evangelismos). The study involved adult patients with Metabolically Associated Steatotic Liver Disease (MASLD), also known as fatty liver disease, which affects approximately 25–30% of the global population.
Study findings
The results of the scientific study conducted by Professor of Internal Medicine-Gastroenterology at the Medical School of the National and Kapodistrian University of Athens, Georgios Papatheodoridis and his colleagues were published in Annals of Gastroenterology, the official journal of the Hellenic Gastroenterological Society.
Patients who received Hepatrat® showed statistically significant improvement in liver enzymes ALT and GGT, with significantly higher rates of simultaneous normalization compared to placebo. Additionally, a significant reduction in liver stiffness was recorded, as assessed by elastography (transient elastography and 2D-shear wave elastography), as well as favorable effects on metabolic parameters, including improvements in glucose levels and total and LDL cholesterol. Long-term administration of the supplement was safe and excellently tolerated, with no reported adverse effects.
Overall, the study findings indicate that Hepatrat® administration in MASLD patients leads to significant improvements in liver enzymes, liver stiffness, as well as patients’ lipid and blood sugar parameters.
The flagship of the Tsetis Pharmaceutical Group UNI-PHARMA with a 62-year history, is today one of the most dynamic and innovative representatives of the pharmaceutical industry sector in Greece and internationally. It holds the first position in sales (units) of the domestic pharmaceutical market among purely Greek companies. Consistently investing in research, cutting-edge technologies and sustainable development, it places scientific progress at the center of its activities with the goal of substantially contributing to health promotion through innovative products and value-added therapies. The Tsetis Pharmaceutical Group (TFEG) today holds more than 120 patents in its portfolio.
